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Available online 3 December 2008LAU-0901, a novel platelet-activating factor (PAF) receptor antagonist, is highly
neuroprotective in a rodent model of cerebral ischemia. This study was conducted to
establish whether the neuroprotection induced by LAU-0901 persists with chronic survival.
Male Sprague–Dawley rats were anesthetized with isoflurane and subjected to 2 h of
temporary middle cerebral artery occlusion (MCAo) induced by means of a poly-L-lisine-
coated intraluminal nylon suture. Animals were treated with either LAU-0901 (60 mg/kg) or
vehicle (45% cyclodextran) administered i.p. at 2 h from onset of MCAo. They received
neurobehavioral examinations during MCAo (60min) and then at 1, 2, 3, 7, 14, 21 and 28 days
followed by histopathology at 30 days. LAU-0901 significantly improved the behavior
compared to the vehicle group, beginning on day 1 (by 29%, p=0.00007) and persisting
throughout a 30-day survival period (42%, p=0.0001). Compared with vehicle treatment,
LAU-0901 treatment significantly increased volume of non-infarcted brain tissue loss
relative to the unlesioned hemisphere (16.3±4.6% vs. 46.0±10.3%, respectively). These
results establish that LAU-0901 confers enduring ischemic neuroprotection.






Middle cerebral artery occlusion1. Introduction
Platelet-activating factor (PAF) is a lipid mediator released by
many types of cells – such as platelets, monocytes/macro-
phages, neutrophils and endothelial cells – that potently
activates neutrophils, contributing to the pathogenesis of
inflammation, endotoxic shock and lipopolysaccharide-
mediated tissue injury (Bazan, 2003). PAF in the nervous
system serves a dual role. It modulates long-term potentiationeuroscience LSUHSC Neu
.
yev).
er B.V. All rights reserved(Kato et al., 1994; Clark et al., 1992) and memory (Izquierdo et
al., 1995). However, when overproduced, this phospholipid
mediator becomes a potent pro-inflammatory mediator.
During brain ischemia and in other pathologic conditions
involving oxidative stress, PAF concentration increases and, in
turn, it becomes a pro-inflammatory messenger and a
mediator of neurotoxicity (Bazan and Allan, 1998). Excessive
PAF production promotes neuronal damage; inhibition of this
process plays a critical role in neuronal survival androscience Center 2020 Gravier Street, Suite 9B4, Room 946A New
.
Fig. 1 – Total neurological score, which incorporates postural
reflex and forelimb-placing tests (normal score=0, maximal
185B R A I N R E S E A R C H 1 2 5 3 ( 2 0 0 9 ) 1 8 4 – 1 9 0prevention of ischemic brain injury (Aspey et al., 1997; Bozlu et
al., 2007, Tian and Bazan, 2005).
LAU-0901 (2,4,6-Trimethyl-1, 4-Dihydro-Pyridine-3, 5-
Dicarboxylic Acid) is a highly potent and selective PAF receptor
antagonist (Boetkjaer et al., 2007; Cortina et al., 2005; He and
Bazan, 2006). Recently, we have shown that LAU-0901
improved behavior and reduced brain infarction in focal
cerebral ischemia in rats and mice (Belayev et al., 2008). The
dose–response studies in rat and mouse models of transient
middle cerebral artery occlusion (MCAo) showed that 60mg/kg
dosage was highly neuroprotective; thus, this dose was
applied in this study (Belayev et al., 2008). The objective of
the present study was to test the hypothesis that acute LAU-
0901-induced neuroprotection endures in animals allowed to
survive for several weeks after focal ischemic insult.score=12) during MCAo and at various times after treatment.
At60minofMCAo,all animalshadascoreof11 (ofapossible12).
LAU-0901 (n=12) or vehicle (n=11) treatment was
administered at 2 h after onset of ischemia. LAU-0901-treated
rats had a significantly improved neurological score,
compared to the corresponding vehicle group, throughout
the 30-day survival period. Values shown are means±SEM.,
*P<0.05, LAU-0901 vs. vehicle.2. Results
2.1. Physiological variables
There were no significant differences with respect to rectal
and cranial temperatures, arterial blood gases or plasmaTable 1 – Physiological variables
Vehicle (n=11) LAU-0901 (n=10)
Before MCAo (15 min)
Rectal temperature (°C) 36.8±0.07 36.6±0.10
Cranial temperature (°C) 36.7±0.14 36.4±0.11
pH 7.43±0.01 7.42±0.01
PO2, mm Hg 113±6 122±5
PCO2, mm Hg 40.5±1.13 39.7±0.91
Plasma glucose, mg/dL 167±8 165±10
Body weight (g) 294±8 328±7
During MCAo (15 min)
Rectal temperature (°C) 37.0±0.10 36.8±0.09
Cranial temperature (°C) 36.7±0.15 36.6±0.09
pH 7.42±0.01 7.40±0.01
PO2, mm Hg 99±4 101±3
PCO2, mm Hg 41.1±0.97 43.0±0.89
Plasma glucose, mg/dL 146±6 150±6
After MCAo (2 h)
Rectal temperature (°C) 38.3±0.25 38.0±0.31
Cranial temperature (°C) 37.4±0.24 36.9±0.29
During chronic survival
Rectal temperature (°C) 38.0±0.17 37.5±0.61
Body weight (g), 1 day 269±7 300±8
Rectal temperature (°C) 37.1±0.26 37.8±0.13
Body weight (g), 2 days 261±14 297±10
Rectal temperature (°C) 37.2±0.18 37.7±0.16
Body weight (g), 3 days 259±8 296±10 ⁎
Rectal temperature (°C) 37.5±0.15 37.6±0.13
Body weight (g), 1 week 286±10 332±10 ⁎
Rectal temperature (°C) 37.5±0.12 37.7±0.10
Body weight, 2 weeks 328±13 389±8 ⁎
Rectal temperature (°C) 37.2±0.30 37.5±0.18
Body weight, 3 weeks 370±13 428±9 ⁎
Rectal temperature (°C) 37.7±0.21 37.5±0.12
Body weight, 4 weeks 397±9 452±9 ⁎
Values are mean±SEM.
MCAo, middle cerebral artery occlusion.
⁎ different from vehicle group (P<0.05, Student's t-test).glucose between groups (Table 1). LAU-0901-treated rats
significantly increased body weight from day 3, which
persisted throughout the 4-week survival period (Table 1).
2.2. Neurobehavioral assessment
Neurological score was normal (0) in all animals before MCAo.
High-grade contralateral deficits (score, 10–11) were present at
60min ofMCAo in all rats; thus, no animals required exclusion
based on inadequate ischemia. A significant improvement in
neurological score was evident in LAU-0901-treated animalsFig. 2 – Areas of normal (i.e., non-infarcted, non-cystic)
cerebral-hemisphere brain tissue at 30 days after MCAo,
shown for nine rostrocaudal forebrain coronal levels in
LAU-0901- and vehicle-treated rats. Left-hemisphere data
for the vehicle and LAU-0901 groups were pooled since they
were virtually identical. Values shown are means±SEM,
*P<0.05, LAU-0901 vs. vehicle.
Fig. 3 – Integrated volumes of normal (i.e., non-infarcted,
non-cystic) cerebral-hemisphere brain tissue at 30 days after
MCAo in LAU-0901- (n=12) and vehicle- (n=11) treated rats.
Left-hemisphere data for the vehicle and LAU-0901 groups
were pooled since they were virtually identical. Values
shown are means±SEM., *, P<0.05, LAU-0901 vs. vehicle.
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and the score was sustained at every observation point
throughout the 30-day survival period (Fig. 1). There were noFig. 4 – Computer generatedMosaiX processed images (Carl Zeiss
and GFAP (Panels B, D and F) paraffin-embedded brain sections a
vehicle (Panels A and B) and two rats treated with LAU-0901 (Pan
cystic necrosis, and pan-necrosis involves the entire neocortical
contrast, the two rats treated with LAU-0901 show less extensiveadverse behavioral side effects observed with LAU-0901
administration.
2.3. Histopathology
The volume of the left hemisphere contralateral to the
infarction was the same in both treatment groups (LAU-0901,
543±7 mm3; vehicle, 529±7 mm3 p=N.S.); this allowed the
data to be pooled for subsequent analysis. The rostrocaudal
distribution of normal hemispheric tissue areas and the
integrated normal hemisphere volumes are shown in Fig. 2.
Compared to vehicle treatment, LAU-0901 increased the non-
infarcted tissue areas at six of nine coronal levels (Fig. 2).
Integrated right hemisphere volume was reduced compared
with the contralateral hemisphere in both vehicle- and LAU-
0901-treated groups (Fig. 3). However, in LAU-0901-treated
rats, the ratio of right/left hemisphere volume computed in
individual animals averaged 0.88±0.03 (mean±SEM), whereas
the corresponding ration in vehicle-treated rats was 0.72
±0.04. This intergroup difference was highly significant
(p=0.001). Thus, LAU-0901 treatment, on average, resulted in
a 20% relative increase in proportion of non-infarcted tissue.
Treatment with LAU-0901 significantly reduced total lesion
volume compared to the vehicle group (20±6 vs. 68±9 mm3,MicroImaging, Inc, Thornwood,NY) of Nissl (PanelsA, C and E)
t coronal level (bregma+1.2 mm) from a rat treated with
els C–F). The saline-treated rat shows typical appearance of
thickness, extending to subjacent regions (Panels A–B). In
damage (Panels C–F).
Fig. 5 – GFAP (Panel A) and Nissl (Panel B) positive cell counts.
Treatment with LAU-0901 significantly increased GFAP and
Nissl positive cells compared to the saline-treated rats.
Values shown are means±SEM., *, P<0.05, LAU-0901 vs.
vehicle.
187B R A I N R E S E A R C H 1 2 5 3 ( 2 0 0 9 ) 1 8 4 – 1 9 0respectively, p=0.0003). Also, tissue loss and percent (relative
to unlesioned hemisphere) were more severe in vehicle-
compared to LAU-0901-treated rats (149±18 vs. 67±14 mm3
and 43±8 vs. 15±4%, respectively, P<0.003). Fig. 4 presents
Nissl and GFAP brain sections of rats treated with vehicle (A
and B) and LAU-0901 (C and D). Vehicle-treated rats showed
ipsilateral-hemisphere tissue loss and extensive zones of
cystic necrosis. In contrast, rats treatedwith LAU-0901 showed
less extensive cortical and subcortical damage. After 1 month,
a cavity had formed and was surrounded with the GFAP
positive astrocytes. GFAP expression was more prominent in
LAU-0901-treated compared to the vehicle-treated rats and
was found in the boundary zone of the infarct (Figs. 4B and D).
Fig. 5 presents GFAP and Nissl positive cell counts. Treatment
with LAU-0901 significantly increased GFAP and Nissl positive
cells compared to the saline-treated rats. The Nissl positive
cells count was not different between the two groups in Cortex
A, which was severely damaged in the vehicle group after
30 days; only a small number of neurons survived.
Five animals died during the experiments: four rats in the
vehicle group (died on days 1, 2, 6 and 7) and one rat in the
LAU-0901 group (died on day 1). These animals were elimi-
nated from the neurobehavioral and histopathological
analysis.3. Discussion
The results of this study establish that systemic adminis-
tration of LAU-0901, a novel PAF receptor antagonist,
confers marked and enduring neuroprotection, as assessedby both neurobehavioral and histological methods, in
animals followed for 30 days after focal cerebral ischemia.
Neurobehavioral improvement began within 1 day after
insult and endured for 30 days (Fig. 1). The histological
results in LAU-0901-treated animals were concordant with
the neurological outcome: namely, a 20% increase in
preserved brain tissue at 30 days (Fig. 3), a striking
reduction in the incidence of extensive cystic-necrotic
lesions (Fig. 3), and markedly improved microscopic histo-
pathology with increased GFAP and Nissl positive cells
(Fig. 5). These results are very encouraging, because the
neuroprotective efficacy shown with short survival periods
may not necessarily persist during longer survival periods
(Dietrich et al., 1993).
The beneficial effect of LAU-0901 has been shown in a
well-controlled animal model of MCAo in rats, which
produces consistent cortical and subcortical infarcts that
closely resemble the large hemispheric infarcts resulting
from proximalMCAo in patients (Belayev et al., 1996).We also
closely monitored and controlled physiological parameters,
including body and cranial temperatures. Cranial tempera-
ture control is extremely important, as it is essential for
determining the extent of ischemic brain injury (Ginsberg
and Busto, 1998).
It has been established that PAF is one of the key brain
damage factors following cerebral ischemia reperfusion, and
its biological effect is produced via the PAF receptor (Bazan,
2001). PAF receptor is present functionally in brain tissue that
regulates several events. It activates intracellular signaling
cascades, including arachidonic acidmetabolism, intracellular
calcium changes, increase of the tyrosine phosphorylation
and immediate-early gene expression, blood–brain barrier
damage, edema formation and neuronal cell death (Kato et al.,
1994). The tight regulation of the balance between synthesis
(via phospholipases) and degradation (via acetylhydrolases) of
PAF modulates the functions of this lipid messenger. During
ischemia, seizures, and in other pathological conditions
involving oxidative stress, the rates of PAF synthesis and
degradation no longer maintain a modulated PAF pool size;
consequently, the concentration of PAF increases and it
becomes a pro-inflammatory messenger and a mediator of
neurotoxicity (Bazan, 2005). PAF produces cerebral damage by
increasing intracellular calcium concentrations, disrupting
the blood brain barrier, reducing cerebral blood flow, and
stimulating leucocytes in damaged neuronal tissue (Bazan
and Allan, 1998).
PAF receptor antagonists reduce experimental brain dys-
function with improvement in neuron survival and function
(Bazan, 2005). Recently, we discovered a novel platelet-
activating factor receptor antagonist, LAU-0901, which has
been shown to inhibit apoptosis, to repress the chemo-
taxis of inflammatory cells, to protect photoreceptors from
light-induced oxidative stress, and to inhibit inflammatory
responses in retinal, corneal and neural cells (Boetkjaer
et al., 2007; Cortina et al., 2005; He and Bazan, 2006) (Bazan
et al., 2003).
LAU-0901 was also evaluated in animal models of focal
cerebral ischemia in rats andmice and showedmarked infarct
volume reduction and neurobehavioral improvement at seven
days of survival (Belayev et al., 2008). LAU-0901 treatment (30,
188 B R A I N R E S E A R C H 1 2 5 3 ( 2 0 0 9 ) 1 8 4 – 1 9 060 and 90 mg/kg) significantly reduced total corrected infarct
volume compared to vehicle rats by 76, 88 and 90%,
respectively. Mice treated with LAU-0901 (30 and 60 mg/kg)
reduced total infarction by 29 and 66%, respectively. All doses
of LAU-0901 significantly improved the neurological score
compared with vehicle-treated rats at 24, 48, 72 h and 7 days
(Belayev et al., 2008).
The remarkable effect of LAU-0901 is not completely
understood. Recently we showed that the recovery of LCBF
after 1 h of MCAo was remarkable in LAU-0901-treated mice
(Belayev et al., 2008). In contrast to the vehicle group, LCBF
continually increased in mice treated with LAU-0901 (by 77%)
of baseline at 6 h. Cerebral blood flow improvement is
therefore a likely explanation for the smaller infarction in
the cortical area and, especially, the subcortical area, which is
usually very resistant to any therapeutic intervention. Further
studies are needed to reveal the exact mechanism by which
LAU-0901 protects the brain after focal cerebral ischemia.
Our data show that after 30 days of MCAo: (1) GFAP
expression was found in the boundary zone to the infarct or
in the areas of selective incomplete ischemic necrosis; (2)
GFAP expression was localized to the same areas where
neurons are destined to survive the ischemic insult (detected
by Nissl positive cells count). Glial cells are activated after
brain ischemia. It has been a general conviction that
microglia secretes neurotoxic agents and astrocytes produce
neurotrophic factors (Eddleston and Mucke, 1993). GFAP
reactivity may be associated with neuronal resistance to
ischemic damage. The contributions of astrocytes to normal
brain physiology have been demonstrated by many reports
(Kimelberg andNorenberg, 1989; Tower, 1992). Astrocytes can
release a number of growth factors for neurons (Kimelberg
and Norenberg, 1989). Some of these, such as nerve growth
factor, may stimulate the neuron as a whole as well as
promote neurite growth. Thus, GFAP expression may be
related to a possible “protective” effect on the adjacent
neurons. Our data may be interpreted as evidence for the
engagement of protective mechanisms in astrocytes and
neurons within regions of the brain that remain viable
following focal cerebral ischemia.4. Conclusions
In summary, the present results establish that LAU-0901, a
novel platelet-activating factor receptor antagonist, confers
enduring neuroprotection in an in vivo model of temporary
focal cerebral ischemia compared to the vehicle treatment.
Therefore, a pharmacological agent such as LAU-0901 may
have potential use in treating focal ischemic stroke in the
clinical setting.Fig. 6 – Schematic brain diagram showing locations of regions
for GFAP and Nissl positive cell counts in the cortex (A, B and
C) and striatum (S).5. Experimental procedures
5.1. Protocols and animal care
Experimental protocols were approved by the Institutional
Animal Care and Use Committee of the Louisiana State
University Health Sciences Center, New Orleans.5.2. Focal cerebral ischemia
Twenty-eight adult male Sprague–Dawley rats (260 to 329 g;
Charles River Laboratories, Wilmington, Mass) were fasted
overnight but allowed free access to water. Anesthesia was
inducedwith 3.5% isoflurane in amixture of 70% nitrous oxide
and 30% oxygen. Rats were orally intubated, immobilized with
pancuronium bromide (0.6 mg/kg, intravenous), mechanically
ventilated, and inserted with femoral arterial and venous
catheters for blood sampling and drug infusion. Rectal and
cranial (left temporalis muscle) temperatures were separately
monitored and held at normothermic levels (36–37 °C). Arterial
blood gases, pH and glucose were measured 15 min before,
during, and 15 min after MCAo. The right middle cerebral
artery (MCA) was occluded for 2 h by the intraluminal-
filament method using a poly-L-lysine-coated suture as
previously reported (Belayev et al., 1996). After 2 h of MCAo,
rats were re-anesthetized and the intraluminal suture was
carefully removed. The neck incisions were closed with silk
sutures, and the animals were allowed to survive for 30 days
with free access to food and water.
5.3. Treatment
The agents (LAU-0901; 60 mg/kg; n=12) or vehicle (45%
cyclodextran, 1 ml/kg; n=11) were administered i.p. at the
time of reperfusion, i.e., 2 h from onset of MCAo in rats.
5.4. Behavioral evaluation
A standardized battery of behavioral tests was used to
quantify sensorimotor neurological function during MCAo
(60 min) and then at 1, 2, 3, 7, 14, 21 and 28 days after MCAo
(Belayev et al., 1996). The battery, which incorporates postural
reflex and forelimb-placing tests, yields a 12-point score
(normal=0, maximal=12) (Belayev et al., 1996). Tests were
conducted by an observer blinded to the treatment group.
5.5. Histopathology
Following a 30-day survival period, animals were deeply
anesthetized with isoflurane and perfused transcardially
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maldehyde (4% in phosphate buffer). Then brains were
removed and brain blocks were embedded in paraffin.
Twelve-micron-thick sections were cut in the coronal plane
and stained with thionine (Nissl), and then adjacent sections
were used for glial fibrilliary acidic protein (GFAP) immunos-
taining (Kokubo et al., 2002). Brain sections were then
digitized (MCID™ Core imaging software, InterFocus Imaging
Ltd, Linton, Cambridge, UK) at nine standardized coronal
levels (bregma levels: +5.2, +2.7, +1.2, −0.3, −1.3,−1.8, −3.8,
−5.0 and −7.3 mm) (Konig and Klippel, 1963). Image analysis
was conducted by an operator blinded to the treatment group
assignment. Since chronic histopathology of untreated focal
ischemic infarction involves extensive tissue loss with
residual cavitation, cystic alterations, and ventricular dilata-
tion, image analysis consisted of outlining the areas of the
lesion (which were clearly demarcated), left and right
ventricles, and the left- (contralateral) and right- (MCAo)
hemisphere contours at each level. The following analysis
was conducted: (A) Lesion volume was calculated as the
product of the cross-sectional area for all sections, and the
distance between the sections was determined using Simp-
son's method (Carnevale, 1986). (B) Residual (normal) tissue in
the right hemisphere (mm3) was calculated applying the
following formula: (right hemisphere volume−right ventricle
− lesion volume). (C) Tissue loss was calculated as a difference
in the amount of histologically-intact residual tissue between
the lesioned and the unlesioned hemispheres. (D) Percent
[relative to unlesioned (left) hemisphere volume] was calcu-
lated applying the following formula: (Tissue loss×100/
Residual tissue in left hemisphere). GFAP and Nissl positive
cell counts were conducted in the cortex (A, B and C) and
striatum (S) at the level of the central lesion (bregma level
−0.3 mm; Fig. 6). Data were expressed as numbers of GFAP and
Nissl positive cells per high-power microscopic field
(magnification×40).
5.6. Statistical analysis
Data were presented as mean values±SEM. Neurobehavioral
scores and infarct size data were analyzed by repeated-
measures analysis of variance (ANOVA) with post hoc
Banferroni tests. Physiological variables were compared
using Student t tests. Differences at P<0.05 were considered
statistically significant.Acknowledgments
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